{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:51Z","timestamp":1753891851139,"version":"3.41.2"},"reference-count":5,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2023.1224528","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:32:50Z","timestamp":1687782770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Novel targeted drugs for indolent lymphoid malignancies"],"prefix":"10.3389","volume":"13","author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Pu\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-022-01764-1","article-title":"A comparison of the international consensus and 5th world health organization classifications of mature b-cell lymphomas","volume":"37","author":"Falini","year":"2023","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting bruton\u2019s tyrosine kinase in cancers: drug development advances","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00209","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221142133","article-title":"CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma","volume":"13","author":"Mohty","year":"2022","journal-title":"Ther Adv Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1224528\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:32:54Z","timestamp":1687782774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1224528\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":5,"alternative-id":["10.3389\/fonc.2023.1224528"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1224528","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"article-number":"1224528"}}